Literature DB >> 15619276

Percutaneous transluminal angioplasty of infrapopliteal arteries in patients with intermittent claudication: acute and one-year results.

Hans Krankenberg1, Ina Sorge, Thomas Zeller, Thilo Tübler.   

Abstract

In advanced stages of infrapopliteal peripheral arterial occlusive disease with critical ischemia of the lower limb, the efficacy of percutaneous transluminal angioplasty (PTA) is well established. In contrast, PTA is currently not the therapy of choice in intermittent claudication (IC). In this prospective study, patients with IC were treated percutaneously. Technical aspects and long-term results are presented. In 78 patients (61 males, or 78.2%; age, 71 +/- 11 years) with IC (Rutherford grade 2 or 3), 104 interventions were performed. At baseline, the initial/absolute walking distance (IWD/AWD) was 49 +/- 34/102 +/- 88 m; the ankle-brachial index (ABI) was 0.61 +/- 0.2 before and 0.49 +/- 0.2 after exercise. A crossover approach was used in 74% and an antegrade access in 26% of the cases. In 19 interventions (18.3%), the excimer laser technique was used, and in 26 interventions (25%) a total of 39 stents were implanted. Procedural success rate was 89.4%. IWD and AWD improved to 107 +/- 67 m and 167 +/- 74 m (P < 0.0001 vs. baseline each), respectively, and the ABI at rest and after exercise increased to 0.88 +/- 0.13 and 0.72 +/- 0.19 (P < 0.0001 vs. baseline each). Six complications occurred (5.8%). One embolic occlusion, two minor groin hematoma, one arteriovenous fistula, one compartment syndrome, and one perforation. All were treated conservatively. After 12 months, the primary patency rate was 66.3%, cumulative primary assisted patency rate was 81.9%, and secondary patency rate was 91.5%. Percutaneous revascularization of infrapopliteal arteries in patients with IC is feasible and associated with good acute clinical results and an encouraging long-term patency rate. The complication rate is low.

Entities:  

Mesh:

Year:  2005        PMID: 15619276     DOI: 10.1002/ccd.20237

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  7 in total

Review 1.  [PTA and stent placement distal to the superficial femoral artery].

Authors:  T Rand; M Haumer; A Stadler; M Schoder; J Kettenbach
Journal:  Radiologe       Date:  2006-11       Impact factor: 0.635

Review 2.  Endovascular intervention for peripheral artery disease.

Authors:  Arun K Thukkani; Scott Kinlay
Journal:  Circ Res       Date:  2015-04-24       Impact factor: 17.367

3.  Ten years after arterial bypass surgery for claudication: venous bypass is the primary procedure for TASC C and D lesions.

Authors:  Thomas Eugster; Regula Marti; Lorenz Gurke; Peter Stierli
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

4.  The evaluation of primary stenting of sirolimus-eluting versus bare-metal stents in the treatment of atherosclerotic lesions of crural arteries.

Authors:  Aleksander Falkowski; Wojciech Poncyljusz; Grazyna Wilk; Małgorzata Szczerbo-Trojanowska
Journal:  Eur Radiol       Date:  2008-11-26       Impact factor: 5.315

5.  Self-expanding nitinol stents for treatment of infragenicular arteries following unsuccessful balloon angioplasty.

Authors:  Gunnar Tepe; Thomas Zeller; Stephan Heller; Jakub Wiskirchen; Arne Fischmann; Stephan Coerper; Bernd Balletshofer; Stefan Beckert; Claus D Claussen
Journal:  Eur Radiol       Date:  2006-12-21       Impact factor: 7.034

6.  Critical limb ischaemia in a diabetic population from an Asian Centre: angiographic pattern of disease and 3-year limb salvage rate with percutaneous angioplasty as first line of treatment.

Authors:  M Tan; U Pua; D E S Wong; S J Punamiya; G C Chua; N Teo
Journal:  Biomed Imaging Interv J       Date:  2010-10-01

7.  Clinical outcomes of infrapopliteal angioplasty in patients with critical limb ischemia.

Authors:  Hyeon Min Ryu; Jung-Sun Kim; Young Guk Ko; Myeong-Ki Hong; Yangsoo Jang; Donghoon Choi
Journal:  Korean Circ J       Date:  2012-04-26       Impact factor: 3.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.